NYSEARCA:BBH

Vaneck Vectors Biotech Etf ETF News

etoro logo Buy BBH
*Your capital is at risk
$205.55
-4.58 (-2.18%)
At Close: Jul 10, 2026
iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries signific
State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40
Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC h
Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices
The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
Launched on December 20, 2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
The 2026 Brown Brothers Harriman (BBH) Global ETF Investor Survey revealed a constant data point — demand for ETFs remains robust on a global scale. However, the current market environment is shifti
VanEck Biotech ETF (NASDAQ: BBH - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 14,260 shares,
VanEck Biotech ETF (NASDAQ: BBH - Get Free Report) and Compass Diversified (NYSE: CODI - Get Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the
BBH: Mature Biotech Exposure, But Limited Growth Ahead
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20,
NEW YORK--(BUSINESS WIRE)--VanEck announced today the 2025 annual distributions per share for its VanEck equity exchange-traded funds.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE